Anti-SYUA/ SNCA/ NACP monoclonal antibody
Anti-SYUA/ SNCA/ NACP antibody for FACS & in-vivo assay
Go to SNCA/SNCA products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T03644-Ab-1/ GM-Tg-hg-T03644-Ab-2 | Anti-Human SNCA monoclonal antibody | Human |
GM-Tg-rg-T03644-Ab-1/ GM-Tg-rg-T03644-Ab-2 | Anti-Rat SNCA monoclonal antibody | Rat |
GM-Tg-mg-T03644-Ab-1/ GM-Tg-mg-T03644-Ab-2 | Anti-Mouse SNCA monoclonal antibody | Mouse |
GM-Tg-cynog-T03644-Ab-1/ GM-Tg-cynog-T03644-Ab-2 | Anti-Cynomolgus/ Rhesus macaque SNCA monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T03644-Ab-1/ GM-Tg-felg-T03644-Ab-2 | Anti-Feline SNCA monoclonal antibody | Feline |
GM-Tg-cang-T03644-Ab-1/ GM-Tg-cang-T03644-Ab-2 | Anti-Canine SNCA monoclonal antibody | Canine |
GM-Tg-bovg-T03644-Ab-1/ GM-Tg-bovg-T03644-Ab-2 | Anti-Bovine SNCA monoclonal antibody | Bovine |
GM-Tg-equg-T03644-Ab-1/ GM-Tg-equg-T03644-Ab-2 | Anti-Equine SNCA monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T03644-Ab-1/ GM-Tg-hg-T03644-Ab-2; GM-Tg-rg-T03644-Ab-1/ GM-Tg-rg-T03644-Ab-2; GM-Tg-mg-T03644-Ab-1/ GM-Tg-mg-T03644-Ab-2; GM-Tg-cynog-T03644-Ab-1/ GM-Tg-cynog-T03644-Ab-2; GM-Tg-felg-T03644-Ab-1/ GM-Tg-felg-T03644-Ab-2; GM-Tg-cang-T03644-Ab-1/ GM-Tg-cang-T03644-Ab-2; GM-Tg-bovg-T03644-Ab-1/ GM-Tg-bovg-T03644-Ab-2; GM-Tg-equg-T03644-Ab-1/ GM-Tg-equg-T03644-Ab-2 |
Products Name | Anti-SNCA monoclonal antibody |
Format | mab |
Target Name | SNCA |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Diagnostic target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-SNCA benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Target information
Target ID | GM-T03644 |
Target Name | SNCA |
Gene ID | 6622,20617,29219,706985,478478,101091694,282857,100053270 |
Gene Symbol and Synonyms | alpha-Syn,alphaSYN,NACP,PARK1,PARK4,PD1,SNCA |
Uniprot Accession | P37840,P37377,P61143,Q3T0G8 |
Uniprot Entry Name | SYUA_HUMAN,SYUA_MACMU,SYUA_RAT,SYUA_BOVIN |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, Diagnostics Biomarker, INN Index |
Disease | N/A |
Gene Ensembl | ENSG00000145335 |
Target Classification | N/A |
The target: SNCA, gene name: SNCA, also named as NACP, PARK1, PARK4, PD1. Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Alternatively spliced transcripts encoding different isoforms have been identified for this gene. [provided by RefSeq, Feb 2016].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.